Inspire(US:INSP) Prnewswireยท2025-11-10 18:32Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the launch of its Inspire V device for obstructive sleep apnea, which reportedly encountered significant demand issues and operational challenges [4][5]. Company Overview - Inspire Medical develops and manufactures an implantable medical device called "Inspire" for the treatment of obstructive sleep apnea, with the latest version being Inspire V, which includes an implanted sensor and neurostimulator designed to enhance respiration during sleep [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, Inspire Medical and its executives made false statements and failed to disclose critical issues, including poor demand for Inspire V and excess inventory at providers, which hindered the transition to the new treatment [4]. - It is alleged that the launch of Inspire V was not successful, as many centers did not complete necessary training and onboarding, and software updates for billing were delayed, impacting the ability to process claims [5]. Impact on Financial Guidance - Following the revelation of these issues on August 4, 2025, Inspire Medical reduced its 2025 earnings guidance by over 80%, leading to a more than 32% decline in the company's stock price [5]. Legal Process for Lead Plaintiff - Investors who purchased Inspire Medical common stock during the class period have until January 5, 2026, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief in class action cases [7].